Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

Marc Carrier 1 Karim Abou-Nassar Ranjeeta Mallick Vicky Tagalakis 2 Sudeep Shivakumar 3 Silvana Spadafora Katerine Marquis Mateya Trinkaus Anna Tomiak Agnès Lee 4 Peter Gross Alejandro Lazo-Langner 5 Robert El-Maraghi Glenwood Goss Grégoire Le Gal 6 David Stewart 7 Timothy Ramsay 8 Marc Rodger 9 Debra Witham Philip Wells 10
1 Thrombosis Program
2 Dep Med - MONTREAL - Department of Medicine
3 Dep Med - HALIFAX - Department of Medicine
4 Columbia University [New York]
5 Dep Med - LONDON - CANADA - Department of Medicine
6 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
7 School of Environmental Sciences [Norwich]
8 Clinical Epidemiology Unit
9 OHRI - Ottawa Hospital Research Institute [Ottawa]
10 uOttawa - University of Ottawa [Ottawa]
Abstract : Patients with active cancer have an increased risk of venous thromboembolism, which results in substantial morbidity, mortality, and health care expenditures. The Khorana score (range, 0 to 6, with higher scores indicating a higher risk of venous thromboembolism) has been validated to identify patients with cancer at elevated risk for this complication and may help select those who could benefit from thromboprophylaxis.
Document type :
Journal articles
Complete list of metadatas
https://hal.univ-brest.fr/hal-02052475
Contributor : Ghislaine Calvez <>
Submitted on : Thursday, February 28, 2019 - 2:43:05 PM
Last modification on : Monday, December 16, 2019 - 6:38:12 PM

Links full text

openaccess

Identifiers

Collections

UNIV-BREST | GETBO | IBSAM

Citation

Marc Carrier, Karim Abou-Nassar, Ranjeeta Mallick, Vicky Tagalakis, Sudeep Shivakumar, et al.. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine, Massachusetts Medical Society, 2019, 380 (8), pp.711-719. ⟨10.1056/NEJMoa1814468⟩. ⟨hal-02052475⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

55

Contact

Informations

CCSD